留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝移植术后人类疱疹病毒6型感染的研究进展

刘敏 孙丽莹

刘敏, 孙丽莹. 肝移植术后人类疱疹病毒6型感染的研究进展[J]. 器官移植, 2020, 11(4): 502-507, 515. doi: 10.3969/j.issn.1674-7445.2020.04.014
引用本文: 刘敏, 孙丽莹. 肝移植术后人类疱疹病毒6型感染的研究进展[J]. 器官移植, 2020, 11(4): 502-507, 515. doi: 10.3969/j.issn.1674-7445.2020.04.014
Liu Min, Sun Liying. Research progress on human herpesvirus 6 infection after liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 502-507, 515. doi: 10.3969/j.issn.1674-7445.2020.04.014
Citation: Liu Min, Sun Liying. Research progress on human herpesvirus 6 infection after liver transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(4): 502-507, 515. doi: 10.3969/j.issn.1674-7445.2020.04.014

肝移植术后人类疱疹病毒6型感染的研究进展

doi: 10.3969/j.issn.1674-7445.2020.04.014
基金项目: 

北京市医院管理局“登峰”人才培养计划 DFL20150101

详细信息
    作者简介:

    刘敏,女,1990年生,博士研究生,研究方向为消化内科学,Email: lmlm953@163.com

    通讯作者:

    孙丽莹,女,1967年生,博士,主任医师,研究方向为肝脏移植感染与免疫,Email: sunxlx@outlook.com

  • 中图分类号: R617, R752.1

Research progress on human herpesvirus 6 infection after liver transplantation

More Information
  • 摘要: 人类疱疹病毒6型(HHV-6)初始侵入宿主体内后可终身潜伏,而肝移植受者在免疫抑制期间可出现潜伏感染的再激活。肝移植受者HHV-6感染可导致发热、肝炎、脑炎以及移植物功能障碍,并间接增加了巨细胞病毒(CMV)、丙型肝炎病毒(HCV)感染所致肝纤维化进展的风险。目前,肝移植术后HHV-6感染的发病机制尚未系统阐明,并缺乏有效的防治策略。本文就肝移植术后HHV-6感染的发病机制、危险因素、诊断和治疗方法等方面的进展进行综述。

     

  • [1] ABLASHI D, AGUT H, ALVAREZ-LAFUENTE R, et al. Classification of HHV-6A and HHV-6B as distinct viruses[J]. Arch Virol, 2014, 159(5):863-870. DOI: 10.1007/s00705-013-1902-5.
    [2] SALAHUDDIN SZ, ABLASHI DV, MARKHAM PD, et al. Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders[J]. Science, 1986, 234(4776):596-601. DOI: 10.1126/science.2876520.
    [3] PHAN TL, LAUTENSCHLAGER I, RAZONABLE RR, et al. HHV-6 in liver transplantation: a literature review[J]. Liver Int, 2018, 38(2):210-223. DOI: 10.1111/liv.13506.
    [4] LAUTENSCHLAGER I, RAZONABLE RR. Human herpesvirus-6 infections in kidney, liver, lung, and heart transplantation: review[J]. Transpl Int, 2012, 25(5):493-502. DOI: 10.1111/j.1432-2277.2012.01443.x.
    [5] TESINI BL, EPSTEIN LG, CASERTA MT. Clinical impact of primary infection with roseoloviruses[J]. Curr Opin Virol, 2014, 9:91-96. DOI: 10.1016/j.coviro.2014.09.013.
    [6] YLINEN E, LEHTINEN S, JAHNUKAINEN T, et al. Human herpes virus 6 infection in pediatric organ transplant patients[J]. Pediatr Transplant, 2017, 21(4). DOI: 10.1111/petr.12905.
    [7] PELLETT MADAN R, HAND J, AST Infectious Diseases Community of Practice. Human herpesvirus 6, 7, and 8 in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13518. DOI: 10.1111/ctr.13518.
    [8] KAUFER BB, FLAMAND L. Chromosomally integrated HHV-6: impact on virus, cell and organismal biology[J]. Curr Opin Virol, 2014, 9:111-118. DOI:10.1016/j.coviro. 2014.09.010.
    [9] RAZONABLE RR, ZERR DM, AST Infectious Diseases Community of Practice. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients[J]. Am J Transplant, 2009, 9 (Suppl 4):S100-S103. DOI:10.1111/j.1600-6143. 2009.02899_2.x.
    [10] SAMPAIO AM, GUARDIA AC, MILAN A, et al. Co-infection and clinical impact of human herpesvirus 5 and 6 in liver transplantation[J]. Transplant Proc, 2012, 44 (8):2455-2458. DOI: 10.1016/j.transproceed.2012.07.034.
    [11] AGUT H, BONNAFOUS P, GAUTHERET-DEJEAN A. Laboratory and clinical aspects of human herpesvirus 6 infections[J]. Clin Microbiol Rev, 2015, 28(2):313-335. DOI: 10.1128/CMR.00122-14.
    [12] BONNAFOUS P, MARLET J, BOUVET D, et al. Fatal outcome after reactivation of inherited chromosomally integrated HHV-6A (iciHHV-6A) transmitted through liver transplantation[J]. Am J Transplant, 2018, 18(6): 1548-1551. DOI: 10.1111/ajt.14657.
    [13] DE SIMONE M, MUCCIO CF, MEGNA AS, et al. Human herpes virus 6 encephalitis in immunocompetent patient: an unusual neuroradiological presentation[J]. Clin Neurol Neurosurg, 2013, 115(10):2219-2222. DOI:10.1016/j. clineuro.2013.06.015.
    [14] FUJITA M, TAKAHASHI A, IMAIZUMI H, et al. Drug-induced liver injury with HHV-6 reactivation[J]. Intern Med, 2015, 54(10):1219-1222. DOI: 10.2169/internalmedicine.54.4329.
    [15] FERNÁNDEZ-RUIZ M, KUMAR D, HUSAIN S, et al. Utility of a monitoring strategy for human herpesviruses 6 and 7 viremia after liver transplantation: a randomized clinical trial[J]. Transplantation, 2015, 99(1):106-113. DOI: 10.1097/TP.0000000000000306.
    [16] YASUI T, SUZUKI T, YOSHIKAWA T, et al. Clinical course of human herpesvirus 6 infection in pediatric living donor liver transplantation[J]. Pediatr Transplant, 2018, 22(7):e13239. DOI: 10.1111/petr.13239.
    [17] LAUTENSCHLAGER I, HÖCKERSTEDT K, LINNAVUORI K, et al. Human herpesvirus-6 infection after liver transplantation[J]. Clin Infect Dis, 1998, 26(3): 702-707. DOI: 10.1086/514592.
    [18] OHASHI M, SUGATA K, IHIRA M, et al. Human herpesvirus 6 infection in adult living related liver transplant recipients[J]. Liver Transpl, 2008, 14(1):100-109. DOI: 10.1002/lt.21304.
    [19] ONO Y, ITO Y, KANEKO K, et al. Simultaneous monitoring by real-time polymerase chain reaction of epstein-barr virus, human cytomegalovirus, and human herpesvirus-6 in juvenile and adult liver transplant recipients[J]. Transplant Proc, 2008, 40(10):3578-3582. DOI: 10.1016/j.transproceed.2008.05.082.
    [20] RAZONABLE RR, BURAK KW, VAN CRUIJSEN H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus[J]. Clin Infect Dis, 2002, 35(8):974-981. DOI: 10.1086/342911.
    [21] HÄRMÄ M, HÖCKERSTEDT K, KROGERUS L, et al. Pretransplant human herpesvirus 6 infection of patients with acute liver failure is a risk factor for posttransplant human herpesvirus 6 infection of the liver[J]. Transplantation, 2006, 81(3):367-372. DOI: 10.1097/01.tp.0000195771.83614.0b.
    [22] POLITIKOS I, MCMASTERS M, BRYKE C, et al. Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor[J]. Blood Adv, 2018, 2(12):1367-1370. DOI: 10.1182/bloodadvances.2018015982.
    [23] DAS BB, MUNOZ FM. Screening for chromosomally integrated human herpesvirus 6 status in solid-organ donors and recipients[J]. J Heart Lung Transplant, 2017, 36(4):481. DOI: 10.1016/j.healun.2017.01.004.
    [24] BONNAFOUS P, PHAN TL, HIMES R, et al. Evaluation of liver failure in a pediatric transplant recipient of a liver allograft with inherited chromosomally integrated HHV-6B[J]. J Med Virol, 2020, 92(2):241-250. DOI: 10.1002/jmv.25600.
    [25] LEE SO, BROWN RA, RAZONABLE RR. Clinical significance of pretransplant chromosomally integrated human herpesvirus-6 in liver transplant recipients[J]. Transplantation, 2011, 92(2):224-229. DOI: 10.1097/TP.0b013e318222444a.
    [26] POTENZA L, LUPPI M, BAROZZI P, et al. HHV-6A in syncytial giant-cell hepatitis[J]. N Engl J Med, 2008, 359(6):593-602. DOI: 10.1056/NEJMoa074479.
    [27] BUYSE S, ROQUE-AFONSO AM, VAGHEFI P, et al. Acute hepatitis with periportal confluent necrosis associated with human herpesvirus 6 infection in liver transplant patients[J]. Am J Clin Pathol, 2013, 140(3):403-409. DOI: 10.1309/AJCP0FWI2XAHECBJ.
    [28] BALDWIN K. Ganciclovir-resistant human herpesvirus-6 encephalitis in a liver transplant patient: a case report[J]. J Neurovirol, 2011, 17(2):193-195. DOI: 10.1007/s13365-011-0019-4.
    [29] VINNARD C, BARTON T, JERUD E, et al. A report of human herpesvirus 6-associated encephalitis in a solid organ transplant recipient and a review of previously published cases[J]. Liver Transpl, 2009, 15(10):1242-1246. DOI: 10.1002/lt.21816.
    [30] MAGALHÃES GS, GUARDIA AC, SAMPAIO AM, et al. HHV-6: clinical and laboratory investigations and correlations with encephalitis in liver transplant recipients[J]. Transplant Proc, 2013, 45(5):1997-1999. DOI: 10.1016/j.transproceed.2013.01.095.
    [31] RAZONABLE RR, LAUTENSCHLAGER I. Impact of human herpes virus 6 in liver transplantation[J]. World J Hepatol, 2010, 2(9):345-353. DOI: 10.4254/wjh.v2.i9.345.
    [32] SINGH N, CARRIGAN DR, GAYOWSKI T, et al. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity[J]. Transplantation, 1997, 64(5):674-678. DOI: 10.1097/00007890-199709150-00002.
    [33] PISCHKE S, GÖSLING J, ENGELMANN I, et al. High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis[J]. J Hepatol, 2012, 56(5):1063-1069. DOI: 10.1016/j.jhep.2011.12.017.
    [34] HUMAR A, KUMAR D, RABOUD J, et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation[J]. Am J Transplant, 2002, 2(5):461-466. DOI: 10.1034/j.1600-6143.2002.20511.x.
    [35] DOCKRELL DH, MENDEZ JC, JONES M, et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients[J]. Transplantation, 1999, 67(3):399-403. DOI: 10.1097/00007890-199902150-00010.
    [36] ROGERS J, ROHAL S, CARRIGAN DR, et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome[J]. Transplantation, 2000, 69(12):2566-2573. DOI: 10.1097/00007890-200006270-00016.
    [37] JAMALIDOUST M, ALIABADI N, NAMAYANDEH M, et al. Human herpesvirus 6 as an indicator of cytomegalovirus infection and its attributable disease symptoms in liver transplant recipients[J]. Exp Clin Transplant, 2019, DOI: 10.6002/ect.2019.0119[Epubaheadofprint].
    [38] GUARDIA AC, STUCCHI RS, SAMPAIO AM, et al. Human herpesvirus 6 in donor biopsies associated with the incidence of clinical cytomegalovirus disease and hepatitis C virus recurrence[J]. Int J Infect Dis, 2012, 16(2):e124-e129. DOI: 10.1016/j.ijid.2011.10.008.
    [39] SINGH N, HUSAIN S, CARRIGAN DR, et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients[J]. Clin Transplant, 2002, 16(2):92-96. DOI: 10.1034/j.1399-0012.2002.1o096.x.
    [40] HUMAR A, KUMAR D, CALIENDO AM, et al. Clinical impact of human herpesvirus 6 infection after liver transplantation[J]. Transplantation, 2002, 73(4):599-604. DOI: 10.1097/00007890-200202270-00021.
    [41] KOMAROFF AL, PHAN T, FLAMAND L, et al. Summary of the 9th international conference on human herpesviruses 6 and 7 (HHV-6A, HHV-6B, and HHV-7)[J]. J Med Virol, 2016, 88(12):2038-2043. DOI: 10.1002/jmv.24561.
    [42] CHEVRET L, BOUTOLLEAU D, HALIMI-IDRI N, et al. Human herpesvirus-6 infection: a prospective study evaluating HHV-6 DNA levels in liver from children with acute liver failure[J]. J Med Virol, 2008, 80(6):1051-1057. DOI: 10.1002/jmv.21143.
    [43] LAUTENSCHLAGER I, HÄRMÄ M, HÖCKERSTEDT K, et al. Human herpesvirus-6 infection is associated with adhesion molecule induction and lymphocyte infiltration in liver allografts[J]. J Hepatol, 2002, 37(5):648-654. DOI: 10.1016/s0168-8278(02)00246-5.
    [44] LE J, GANTT S, AST Infectious Diseases Community of Practice. Human herpesvirus 6, 7 and 8 in solid organ transplantation[J]. Am J Transplant, 2013, 13:128-137. DOI: 10.1111/ajt.12106.
    [45] ZERR DM. Human herpesvirus 6 (HHV-6) disease in the setting of transplantation[J]. Curr Opin Infect Dis, 2012, 25(4):438-444. DOI: 10.1097/QCO.0b013e3283553362.
    [46] HUANG C, YAN B, LEI D, et al. Apolipoprotein 4 may increase viral load and seizure frequency in mesial temporal lobe epilepsy patients with positive human herpes virus 6B[J]. Neurosci Lett, 2015, 593:29-34. DOI: 10.1016/j.neulet.2014.12.063.
    [47] SIDDON A, LOZOVATSKY L, MOHAMED A, et al. Human herpesvirus 6 positive Reed-Sternberg cells in nodular sclerosis Hodgkin lymphoma[J]. Br J Haematol, 2012, 158(5):635-643. DOI: 10.1111/j.1365-2141.2012.09206.x.
    [48] LOGINOV R, KARLSSON T, HÖCKERSTEDT K, et al. Quantitative HHV-6B antigenemia test for the monitoring of transplant patients[J]. Eur J Clin Microbiol Infect Dis, 2010, 29(7):881-886. DOI: 10.1007/s10096-010-0923-1.
    [49] CASERTA MT, HALL CB, SCHNABEL K, et al. Diagnostic assays for active infection with human herpesvirus 6 (HHV-6)[J]. J Clin Virol, 2010, 48(1):55-57. DOI: 10.1016/j.jcv.2010.02.007.
    [50] PELLETT PE, ABLASHI DV, AMBROS PF, et al. Chromosomally integrated human herpesvirus 6: questions and answers[J]. Rev Med Virol, 2012, 22(3):144-155. DOI: 10.1002/rmv.715.
    [51] OGATA M, PHAN TL, FUKUDA T. Antiviral therapy for the treatment of HHV-6-associated syndromes after transplant[J]. Am J Transplant, 2019, 19(1):306-307. DOI: 10.1111/ajt.15069.
    [52] BONNAFOUS P, MARLET J, GAUDY-GRAFFIN C, et al. Need for a better characterization of HHV-6 infections and associated clinical impacts[J]. Am J Transplant, 2019, 19(1):304-305. DOI: 10.1111/ajt.15013.
    [53] HILL JA. Human herpesvirus 6 in transplant recipients: an update on diagnostic and treatment strategies[J]. Curr Opin Infect Dis, 2019, 32(6):584-590. DOI: 10.1097/QCO.0000000000000592.
    [54] CHEMALY RF, HILL JA, VOIGT S, et al. In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review[J]. Antiviral Res, 2019, 163:50-58. DOI:10.1016/j.antiviral. 2019.01.008.
    [55] AGUT H, BONNAFOUS P, GAUTHERET-DEJEAN A. Update on infections with human herpesviruses 6A, 6B, and 7[J]. Med Mal Infect, 2017, 47(2):83-91. DOI: 10.1016/j.medmal.2016.09.004.
  • 加载中
计量
  • 文章访问数:  50
  • HTML全文浏览量:  29
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-04-24
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-07-15

目录

    /

    返回文章
    返回